The U.S. Food and Drug Administration has approved Zepbound, a medication for chronic weight management in adults with obesity or overweight. The drug, developed by Eli Lilly and Co., has been proven effective in two randomized, double-blind, placebo-controlled trials. However, the FDA warns that the safety and effectiveness of coadministration of Zepbound with other medications for weight management have not been established. Zepbound also carries warnings for several potential side effects, including pancreatitis, gallbladder problems, hypoglycemia, acute kidney injury, and diabetic retinopathy.